Indaptus Therapeutics Reports Reduced Losses and Increased Assets in Q2 2026

Indaptus Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of approximately $1.8 million, a significant decrease from the $5.2 million loss recorded in the same period of 2025. For the first half of 2026, the company reported a net loss of $4.3 million, down from $9.8 million in the prior year. The reduction in losses is attributed to a substantial decrease in operating expenses, which fell to $1.8 million for the quarter, compared to $4.5 million in the previous year. This decline was primarily driven by reduced research and development costs, which decreased from $2.2 million to $363,127 year-over-year.

The company’s total assets increased to $11.99 million as of June 30, 2026, up from $9.31 million at the end of 2025. This growth was largely due to a successful private placement in June 2026, where Indaptus issued 20 million shares of common stock, raising approximately $12 million before expenses. The company’s cash and cash equivalents stood at $7.55 million, a decrease from $8.51 million at the end of the previous fiscal year, reflecting ongoing operational cash outflows. The total stockholders' equity also saw a significant increase, rising to $11.37 million from $3.15 million at the end of 2025.

In terms of strategic developments, Indaptus entered into a research collaboration with Kunming University of Science and Technology in China, focusing on neurological research and sleep as part of its immunotherapy research. This collaboration is expected to enhance the company’s research capabilities and align with its long-term objectives. Additionally, the company is exploring potential strategic transactions, including investments or acquisitions, to foster growth opportunities. The company’s management is actively evaluating how these initiatives can complement its existing therapeutic development activities.

Operationally, Indaptus has made strides in its research and development efforts, although specific metrics regarding customer counts or product adoption rates were not disclosed in the filing. The company continues to assess opportunities for geographic expansion and the potential for new product lines, particularly in areas related to sleep and immune health. As of June 30, 2026, the company had a total of 133.2 million shares outstanding, reflecting its recent capital-raising activities.

Looking ahead, Indaptus Therapeutics anticipates continued investment in its research and development activities while managing its cash flow to support ongoing operations. The company expects to incur additional losses as it explores strategic opportunities and expands its research initiatives. Management believes that its current financial resources will be sufficient to fund operations through June 30, 2027, although there remains substantial doubt about the company’s ability to continue as a going concern without further capital raises or successful strategic transactions.